The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

This trial looks at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors (NSCLC, HNSCC).

The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).

The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).

The purpose of this clinical trial is to assess whether a medical device called the TIVUS System can lower high blood pressure in patients who are known to have hypertension. 

Eligible patients include those who currently have a diagnosis of high blood pressure despite having taken or currently taking anti-hypertensive medications.

The purpose of this clinical study is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication.

Eligible patients include those who currently have a diagnosis of high blood pressure despite having taken or are currently taking anti-hypertensive medications.